Inhibrx Biosciences reported a net loss of $38.7 million for Q3 2026, with $199.5 million in cash. The company is progressing clinical trials for its cancer drugs ozekibart and ordastobart, with important data readouts expected in mid-2027. Upcoming milestones include updated trial results for Ewing sarcoma and head and neck cancer, plus preparations for potential drug approvals. These developments could impact Inhibrx's future growth and regulatory progress.
Inhibrx's third quarter 2026 financial results provide context for readers following biotech developments. For readers following health-sector stocks, here is Pluang's market snapshot as of Nov 14, 2026 03:21 WIB: Of 150 priced US health-sector stocks tradable on Pluang, 81 rose and 68 fell today. Notable movers include ALNY at USD 164.69 with a 1-day change of +5.13% and 100% buy order activity, ADMA at USD 13.89 up 4.95%, and SMMT at USD 14.42 down 4.34% with 88% buy order activity.
ArrowMark Financial Corp. announced a monthly cash distribution of $0.15 per share for November 2026, payable on November 30 to shareholders of record as of November 23. This distribution reflects the company's ongoing commitment to provide current i...
Liberty Defense Holdings clarified details of its credit facility and term loan with Parabilis, originally announced in 2024. The company’s subsidiary received a $1.8 million term loan and a $2.5 million revolving credit facility, both secured by sub...
Stardust Power announced a $2.8 million net loss for Q3 2026, an improvement from $4.5 million last year, driven by lower administrative costs and warrant value changes. The company is progressing its lithium refinery project in Muskogee, Oklahoma, d...
byNordic Acquisition Corporation, a special purpose acquisition company, has extended its deadline to complete a business combination by one month, moving it from November 12, 2026, to December 12, 2026. This is the fourth of up to twelve possible on...
Texas Pacific Land Corporation reported a high Return on Invested Capital (ROIC) of 30.81%, significantly surpassing its Weighted Average Cost of Capital (WACC) of 7.73%. This strong performance results in the highest ROIC-to-WACC ratio of 3.98 among...
